Treatment of Breast Cancer via a Novel MDM2 Inhibitor

Technology #d-1129

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Dr. Ruiwen Zhang
Dr. Zhang obtained MD (with highest honor) and PhD (Toxicology) from Fudan University Shanghai Medical College and completed a post-doctoral/clinical pharmacology fellowship at University of Alabama School of Medicine (UAB). He joined UAB faculty in 1992 and moved through the ranks to Tenured Professor and Cancer Pharmacology Laboratory Director. He joined TTUHSC School of Pharmacy in July 2010. Dr. Zhang’s research has been continuously funded by NIH, DoD, and other agencies, publishing > 180 papers, 2 books, > 50 invited reviews/book chapters. with >6,800 citations (H-index, 47). He is a certified toxicologist by American Board of Toxicology (D.A.B.T.) and was an ABT Board Director (2009-2013). He is an FDA advisory committee member and study section member for NIH, DoD, CDC, FDA, and NIOSH. Dr. Zhang was elected as Fellow of American Association for the Advancement of Science (AAAS) in 2009. He is Editor-in-Chief of Current Cancer Drug Targets.
External Link (
Managed By
Cameron Smith
Licensing Associate 806-834-6822
Patent Protection

Provisional Patent Application Filed
The pyrido[b]indole ​MDM2 inhibitor ​SP-141 exerts potent therapeutic effects in breast cancer models
Nature Communications, October 1, 2014

Breast cancer has become the most frequently diagnosed cancer in women, and is the second leading cause of death in women. Although relatively ineffective, Mouse Double Mouse Minute 2 (MDM2) inhibitors blocking the MDM2-p53-binding interphase are currently used for the treatment of advanced breast cancer. This new technology targets a novel direct inhibitor of the MdM2 gene --SP141-- that has shown to possess in vitro and in vivo anti-breast cancer activity, with no seen toxicity.

Market Applications:

  • Cancer Diagnostics
  • In Vitro Diagnostics

Features, Benefits & Advantages:

High throughout screening, and computer aided structure-based rational drug design have shown that SP-141 is a novel therapeutic target for the inhibition of the advancement of breast cancer.  SP-141 has shown to inhibit tumor growth in vivo, induce MDM2 protein degradation, and inhibit cell migration in vitro and in vivo.   

  • Novel, less invasive treatment.
  • Less side effects than other drugs currently on the market

Development Stage:

Initial clinical tests have been completed and analyzed to obtain information regarding the efficacy and safety of the compound, as well as its therapeutic value.


The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models. Wang et al., Nat Commun. 2014 Oct 1;5:5086